Our data confirm that VDAC targeting may represent a promising therapeutic direction for severe DMD forms, as recently demonstrated for another VDAC inhibitor olesoxime in a similar severe D2-mdx model [25]. This evidence concerns the gene VDAC1 and Duchenne muscular dystrophy.